Report Contents

  1. Coriell Personalized Medicine Collaborative Research Study Report. This report includes all data included in the clinical report as well as supplemental drug specific interpretations and educational material.
  2. Clinical Report. This report was generated and approved by Coriell’s CLIA certified genotyping laboratory.
Coriell Institute for Medical Research
Coriell Genotyping and Microarray Center
403 Haddon Avenue Camden, NJ 08103
Phone: 856-966-7377 Fax: 856-964-0254
Date of Birth:
Lab Accessioning Number: DEMOSTEVE
Ordering Physician:
Sample Type: Saliva
Gender: Male
Date Collected:
Date Received:
Date of Report: 11/11/2013
Variants tested RESULT Reference Genotype
rs72559745 (SLCO1B1*1) AG A A
rs56061388 (SLCO1B1*3) CT T T
rs4149056 (SLCO1B1*5) TT T T
rs55901008 (SLCO1B1*6) TT T T
^ When the Result for all SLCO1B1 variants tested are the same as the reference, the Combined Result is called SLCO1B1 *1/*1. In some cases, due to technical limitations, your Combined Result may not be able to be determined. It may still be possible to provide an interpretation for such a result based on possible genetic outcomes (for example in rare combinations of non-reference results at more than one variant, or the presence of a “result not available” at one or more variants).
Risk interpretation based on Coriell’s SLCO1B1/Simvastatin Response Genotype Translation Version 1 (November 2013).


This individual is expected to have Intermediate liver uptake activity based on the Combined Genetic Result: SLCO1B1*1/*3

Individuals with intermediate SLCO1B1 liver uptake activity have a moderately increased risk of myopathy when taking a 40 mg/day or higher dose of simvastatin. A reduced dosage or alternate statin drug should be considered.

Test Limitations

DNA-based testing is highly accurate, however there are many sources of potential error including: mis-identification of samples, rare technical errors, trace contamination of PCR reactions, and rare genetic variants that interfere with analysis. There may be other variants in the SLCO1B1 gene that are not included in this test, that influence the response to simvastatin (Zocor®). This test or one or more of its components was developed and its performance characteristics determined by the Coriell Institute for Medical Research. It has not been approved by the Food and Drug Administration (FDA). The FDA has determined that such approval is not necessary. The Coriell Institute is regulated under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 as qualified to perform high-complexity testing.

Test Methodology

Saliva samples were collected using Oragene DNA Collection Kits (DNA Genotek) and DNA was extracted manually according to the manufacturer’s instructions or automatically using a DNAdvance Kit (Agencourt). Purified DNA was quantified using UV absorbance at 260 nm. One microgram of the resulting DNA from each sample was used as template in the Affymetrix DMET Plus GeneChip assay. Data analysis was performed using Affymetrix DMET Console software.

electronically signed by
Marie Hoover, PhD, Laboratory Director


  1. Bailey KM, et al. Circ Cardiovasc genet 2010; 3:276-285.
  2. Donnelly LA, et al. Clin. Pharmacol Ther 2011; 89:210-216.
  3. Group SC, et al. NEJM 2008; 359:789-799.
  4. Ho RH, et al. Gastroenterol 2006, 130:1793-1806.
  5. Ho RH, et al. Pharmacogenet Genomics 2007; 17:647-656.
  6. Igel M, et al. Clin Pharmacol Ther 2006; 79:419-426.
  7. Kameyama Y, et al. Pharmacogenet Genomics 2005, 15:513-522.
  8. Kivisto KT, Niemi M Pharmaceutical research 2007; 24:239-247.
  9. Lee E, et al.Clin Pharmacol Ther 2005; 78:330-341.
  10. Lee YJ, et al. Inter J Clin Pharmacol Ther 2010; 48:36-45.
  11. Mwinyi J, et al. Clin Pharmacol Ther 2004; 75:415-421.
  12. Niemi M, et al. Pharmacogenet 2004; 14:429-440.
  13. Niemi M, et al. Pharmacogenet Genomics 2005; 15:303-309.
  14. Niemi M Pharmacogenomics 2007; 8:787-802.
  15. Nishizato Y, et al. Clin Pharmacol Ther 2003; 73:554-565.
  16. Pasanen MK, et al. Pharmacogenet Genomics 2006; 16:873-879.
  17. Pasanen MK, et al. Pharmacogenomics 2008; 9:19-33.
  18. Takane H, et al. J Hum Genet 2006; 51:822-826.
  19. Thompson JF, et al. Pharmacogenomics J 2005; 5:352-358.
  20. Tirona RG, et al. J biol chem 2001; 276:35669-35675.
  21. Voora D, et al. JACC 2009; 54:1609-1616.